

Alastair M Thompson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11209500/publications.pdf>

Version: 2024-02-01

85
papers

9,475
citations

186265

28
h-index

60623

81
g-index

87
all docs

87
docs citations

87
times ranked

15087
citing authors

#	ARTICLE	IF	CITATIONS
1	BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. <i>Academic Radiology</i> , 2022, 29, S35-S41.	2.5	7
2	Low-risk DCIS. What is it? Observe or excise?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 21-32.	2.8	9
3	Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study. <i>Breast</i> , 2022, 61, 145-155.	2.2	12
4	Breast screening atypia and subsequent development of cancer: protocol for an observational analysis of the Sloane database in England (Sloane atypia cohort study). <i>BMJ Open</i> , 2022, 12, e058050.	1.9	4
5	Abstract GS1-08: CCTGMA.32, a phase III randomized double-blind placebo controlled adjuvant trial of metformin (MET) vs placebo (PLAC) in early breast cancer (BC): Results of the primary efficacy analysis (clinical trials.gov NCT01101438). <i>Cancer Research</i> , 2022, 82, GS1-08-GS1-08.	0.9	4
6	Abstract P3-18-10: Current options and future perspectives for breast margin assessment in clinical practice. <i>Cancer Research</i> , 2022, 82, P3-18-10-P3-18-10.	0.9	0
7	Abstract P1-22-01: Predictors of inaccurate pre-operative size assessment of screen detected DCIS and impact on recurrence rates. <i>Cancer Research</i> , 2022, 82, P1-22-01-P1-22-01.	0.9	0
8	“œls it cancer or not?œA qualitative exploration of survivor concerns surrounding the diagnosis and treatment of ductal carcinoma in situ. <i>Cancer</i> , 2022, 128, 1676-1683.	4.1	6
9	Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer. <i>Ultrasound in Medicine and Biology</i> , 2022, , .	1.5	2
10	Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 1323.	3.7	4
11	A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. <i>European Journal of Radiology</i> , 2022, 149, 110220.	2.6	13
12	Exercise to prevent shoulder problems after breast cancer surgery: the PROSPER RCT. <i>Health Technology Assessment</i> , 2022, 26, 1-124.	2.8	9
13	Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2878-2889.	7.0	10
14	Quantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in <scp>TripleœNegative</scp> Breast Cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 56, 1901-1909.	3.4	6
15	Effect of Metformin vs Placebo on Invasive DiseaseœFree Survival in Patients With Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1963.	7.4	81
16	Improving outcomes for women aged 70 years or above with early breast cancer: research programme including a cluster RCT. <i>Programme Grants for Applied Research</i> , 2022, 10, 1-114.	1.0	1
17	Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project. <i>British Journal of Cancer</i> , 2021, 124, 1009-1017.	6.4	29
18	Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). <i>Breast Cancer Research and Treatment</i> , 2021, 185, 1-12.	2.5	10

#	ARTICLE	IF	CITATIONS
19	Bridging the Age Gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer. <i>European Journal of Cancer</i> , 2021, 144, 269-280.	2.8	37
20	Reply to "Comment on: Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project". <i>British Journal of Cancer</i> , 2021, 124, 1463-1464.	6.4	2
21	Abstract PD6-06: Radiomic phenotypes from dynamic contrast-enhanced MRI (DCE-MRI) parametric maps for early prediction of response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC) patients. , 2021, , .		1
22	Functional Tumor Volume by Fast Dynamic Contrast-Enhanced MRI for Predicting Neoadjuvant Systemic Therapy Response in Triple-Negative Breast Cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 54, 251-260.	3.4	18
23	70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. <i>Lancet Oncology</i> , The, 2021, 22, 476-488.	10.7	179
24	Bridging The Age Gap: observational cohort study of effects of chemotherapy and trastuzumab on recurrence, survival and quality of life in older women with early breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 209-219.	6.4	26
25	FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036. <i>Npj Breast Cancer</i> , 2021, 7, 51.	5.2	11
26	Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial. <i>Npj Breast Cancer</i> , 2021, 7, 74.	5.2	16
27	Cancer Antigen 15-3/Mucin Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab066.	2.9	5
28	Observational cohort study in older women with early breast cancer: Use of radiation therapy and impact on health-related quality of life and mortality. <i>Radiotherapy and Oncology</i> , 2021, 161, 166-176.	0.6	11
29	Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6115-6123.	7.0	9
30	Exercise versus usual care after non-reconstructive breast cancer surgery (UK PROSPER): multicentre randomised controlled trial and economic evaluation. <i>BMJ</i> , The, 2021, 375, e066542.	6.0	18
31	Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline <i>BRCA</i> Pathogenic Variant. <i>Journal of Clinical Oncology</i> , 2020, 38, 388-394.	1.6	151
32	p63/p40 correlates with the location and phenotype of basal/mesenchymal cancer stem-like cells in human ER ⁺ and HER2 ⁺ breast cancers. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 83-93.	3.0	13
33	Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin. <i>British Journal of Cancer</i> , 2020, 122, 258-265.	6.4	28
34	Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. <i>European Journal of Radiology</i> , 2020, 130, 109170.	2.6	4
35	Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 60.	5.2	9
36	De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ. <i>JAMA Oncology</i> , 2020, 6, 1117.	7.1	3

#	ARTICLE	IF	CITATIONS
37	Quantitative 3-Dimensional Photographic Assessment of Breast Cosmesis After Whole Breast Irradiation for Early Stage Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. <i>Advances in Radiation Oncology</i> , 2020, 5, 824-833.	1.2	7
38	Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1186-1197.	1.6	10
39	Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome. <i>Clinical Cancer Research</i> , 2020, 26, 1977-1984.	7.0	9
40	The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review. <i>Breast</i> , 2020, 50, 95-103.	2.2	7
41	Breast conservation therapy versus mastectomy for breast cancer. <i>Lancet Oncology</i> , The, 2020, 21, 493-494.	10.7	5
42	Effectiveness and Safety of Magseed Localization for Excision of Breast Lesions. <i>Annals of Surgery Open</i> , 2020, 1, e008.	1.4	18
43	The time-varying effect of radiotherapy after breast-conserving surgery for DCIS. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 221-230.	2.5	3
44	Ductal carcinoma in situ: to treat or not to treat, that is the question. <i>British Journal of Cancer</i> , 2019, 121, 285-292.	6.4	168
45	SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 3510-3516.	1.5	47
46	Are baseline ultrasound and mammographic features associated with rates of pathological completes response in patients receiving neoadjuvant chemotherapy for breast cancer?. <i>Cancer Imaging</i> , 2019, 19, 67.	2.8	19
47	Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 3484-3492.	1.6	30
48	The circular RNome of primary breast cancer. <i>Genome Research</i> , 2019, 29, 356-366.	5.5	85
49	Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2206-2216.	1.6	152
50	Imaging features of triple-negative breast cancers according to androgen receptor status. <i>European Journal of Radiology</i> , 2019, 114, 167-174.	2.6	14
51	<p>Comparison of the 7th and 8th edition of American Joint Committee on Cancer (AJCC) staging systems for breast cancer patients: a Surveillance, Epidemiology and End Results (SEER) Analysis</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 1433-1442.	1.9	32
52	Variability in diagnostic threshold for comedo necrosis among breast pathologists: implications for patient eligibility for active surveillance trials of ductal carcinoma in situ. <i>Modern Pathology</i> , 2019, 32, 1257-1262.	5.5	27
53	Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy. <i>British Journal of Radiology</i> , 2018, 91, 20180123.	2.2	11
54	Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. <i>European Journal of Surgical Oncology</i> , 2018, 44, 429-435.	1.0	62

#	ARTICLE	IF	CITATIONS
55	Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy. <i>Breast Cancer Research</i> , 2018, 20, 27.	5.0	17
56	Randomised controlled trial of exercise to prevent shoulder problems in women undergoing breast cancer treatment: study protocol for the prevention of shoulder problems trial (UK PROSPER). <i>BMJ Open</i> , 2018, 8, e019078.	1.9	22
57	A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage. <i>Nature Communications</i> , 2018, 9, 1107.	12.8	63
58	Analysis of stereotactic biopsies performed on suspicious calcifications identified within 24 months after completion of breast conserving surgery and radiation therapy for early breast cancer: Can biopsy be obviated?. <i>American Journal of Surgery</i> , 2018, 215, 693-698.	1.8	7
59	Are There Alternative Strategies for the Local Management of Ductal Carcinoma in Situ?. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 69-80.	1.5	4
60	Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. <i>Molecular Cell</i> , 2018, 71, 606-620.e7.	9.7	491
61	A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers. <i>Nature Genetics</i> , 2017, 49, 341-348.	21.4	75
62	HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. <i>Nature Medicine</i> , 2017, 23, 517-525.	30.7	769
63	Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype. <i>Oncologist</i> , 2017, 22, 394-401.	3.7	21
64	Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. <i>Nature</i> , 2017, 543, 714-718.	27.8	229
65	Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 653-663.	2.4	44
66	Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement. <i>Practical Radiation Oncology</i> , 2017, 7, 73-79.	2.1	483
67	Longitudinal analysis of patient-reported outcomes and cosmesis in a randomized trial of conventionally fractionated versus hypofractionated whole-breast irradiation. <i>Cancer</i> , 2016, 122, 2886-2894.	4.1	29
68	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. <i>Nature</i> , 2016, 534, 47-54.	27.8	1,760
69	A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer. <i>BMC Cancer</i> , 2016, 16, 745.	2.6	14
70	70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 717-729.	27.0	1,427
71	The topography of mutational processes in breast cancer genomes. <i>Nature Communications</i> , 2016, 7, 11383.	12.8	235
72	Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. <i>Nature Communications</i> , 2016, 7, 12910.	12.8	119

#	ARTICLE	IF	CITATIONS
73	Effects of Standard Treatments for Ductal Carcinoma In Situ—Making Informed Choices. <i>JAMA Oncology</i> , 2016, 2, 396.	7.1	6
74	Comparing computer-generated and pathologist-generated tumour segmentations for immunohistochemical scoring of breast tissue microarrays. <i>British Journal of Cancer</i> , 2015, 113, 1075-1080.	6.4	33
75	Do participants in adjuvant breast cancer trials reflect the breast cancer patient population?. <i>European Journal of Cancer</i> , 2015, 51, 907-914.	2.8	15
76	Macroscopic handling and reporting of breast cancer specimens pre- and post-neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches. <i>Histopathology</i> , 2015, 67, 279-293.	2.9	26
77	Intraoperative Radiotherapy: Is it Ready for Prime Time?. <i>Current Breast Cancer Reports</i> , 2015, 7, 15-21.	1.0	0
78	Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation. <i>JAMA Oncology</i> , 2015, 1, 931.	7.1	216
79	RE: Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv065-djv065.	6.3	6
80	Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. <i>Genome Research</i> , 2015, 25, 814-824.	5.5	69
81	Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer. <i>Oncotarget</i> , 2015, 6, 21685-21703.	1.8	24
82	A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer. <i>BMJ Open</i> , 2014, 4, e005285-e005285.	1.9	59
83	Molecular Pathways: Preclinical Models and Clinical Trials with Metformin in Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 2508-2515.	7.0	45
84	The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase. <i>European Journal of Cancer</i> , 2011, 47, 2742-2749.	2.8	99
85	Telomere reduction in human colorectal carcinoma and with ageing. <i>Nature</i> , 1990, 346, 866-868.	27.8	1,612